Work

PSMA-targeted actinium-225 therapy in metastatic castration-resistant prostate cancer (mCRPC): Baseline and follow-up PSMA PET parameters associated with outcomes.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.5070

Authors: Valentina Marulanda Corzo, Charlene Thomas, Gabriel T. Raab, Aaron N. Holmes, Tobechukwu Joseph Okobi, Andres Ricaurte Fajardo, Amie Patel, Zachary Davidson, Samuel Francis Ruder, Pier VItale Nuzzo, Divya Yadav, Sandra Huicochea Castellanos, David M. Nanus, Neil Harrison Bander, Joseph Reginald Osborne, Scott T. Tagawa

Institutions: Weill Cornell Medicine, NewYork–Presbyterian Hospital, Weill Cornell Medical Center

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Prostate Cancer Foundation, National Institutes of Health

OpenAlex ID: W4410815013

Cites:

Cited by: 2

Related to: 10